chufangao/CTO huggingface dataset:
Clinical trial NCT03113084: Study With Heparin Sodium in Subcutaneous Administration
Official title: Phase I Study With Pharmacodynamic Determination of Unfractionated Heparin of Porcine Origin of the Company União Química of Subcutaneous Use in Healthy Participants
Sponsor: União Química Farmacêutica Nacional S/A (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Delay in the R\&D stage
Enrollment: 38.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2022-08-20
Primary completion date: 2023-04-20
Completion date: 2023-10-10
Plan to share individual participant data: NO
Clinical trial NCT04860817: A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
Official title: Investigating the Safety and Efficacy of Anti-CD7 CAR-T Cell Immunotherapy in Patients With Relapse and Refractory T-cell Acute Lymphoblastic Leukemia or T Lymphoblastic Lymphoma
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No proper participant is found.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-01
Primary completion date: 2023-04-30
Completion date: 2023-11-01
Plan to share individual participant data: NO
Clinical trial NCT03479203: Acute Effects of E-Cigarette Aerosol Inhalation
Official title: Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-22
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Baseline population: Pre-intervention status (i.e. pre-vaping).
Plan to share individual participant data: NO
Clinical trial NCT05458102: Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
Official title: A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A, P-glycoprotein (P-gp), and Breast Cancer Resistant Protein (BCRP) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision to change the clinical development plan of this molecule. This decision is not based on efficacy or safety concerns.
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-08-19
Primary completion date: 2023-10-13
Completion date: 2023-10-13
Plan to share individual participant data: NO
Clinical trial NCT02626130: Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
Official title: A Pilot Study of Tremelimumab With or Without Tissue Cryoablation in Patients With Metastatic Renal Cell Carcinoma
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-03-30
Primary completion date: 2022-06-20
Completion date: 2022-06-20
Clinical trial NCT05330429: Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Official title: A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Acronym: ELEVATE CRC
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision to terminate study
Enrollment: 77.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-07-08
Primary completion date: 2024-06-26
Completion date: 2024-06-26
Plan to share individual participant data: NO
Clinical trial NCT03125902: A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
Official title: A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Acronym: IMpassion131
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 653.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-25
Primary completion date: 2019-11-15
Completion date: 2023-01-17
Clinical trial NCT02981082: Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Official title: A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Low recruitment
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-12-31
Primary completion date: 2020-02-10
Completion date: 2020-02-10
Limitations and caveats: Early study termination due to low recruitment; not enough participants for statistically reliable analyses.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT01615055: Fluoxetine Prevention Trial
Official title: Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment
Sponsor: University of California, Los Angeles (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study withdrawn. No participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-30
Primary completion date: 2020-10-31
Completion date: 2020-10-31
Clinical trial NCT05284032: A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)
Official title: A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients
Sponsor: University of Virginia (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-11-29
Primary completion date: 2024-06-11
Completion date: 2024-06-11
Plan to share individual participant data: NO
Clinical trial NCT03576963: Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
Official title: A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer
Sponsor: University of Southern California (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-30
Primary completion date: 2022-01-30
Completion date: 2023-01-30
Clinical trial NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Official title: VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Acronym: VERACITY
Sponsor: Veru Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Administrative reasons
Enrollment: 105.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-24
Primary completion date: 2023-05-04
Completion date: 2023-05-04
Plan to share individual participant data: NO
Clinical trial NCT04671082: Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Official title: A Phase 3, 14-Day, Double-blind, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Acronym: RESUME-1
Sponsor: Neurana Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1004.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-12-15
Primary completion date: 2021-12-13
Completion date: 2022-03-21
Plan to share individual participant data: NO
Clinical trial NCT02120365: Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
Official title: Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
Sponsor: Virginia Commonwealth University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-06-01
Primary completion date: 2022-02-15
Completion date: 2022-02-16
Baseline population: Non-treatment seeking heavy drinkers- This is a crossover design. Subjects each completed at least one of the three dosages for a lab day.
Plan to share individual participant data: NO
Clinical trial NCT04323631: Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
Official title: Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
Sponsor: Rambam Health Care Campus (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Trial not started due to accumulating evidence against HCQ for COVID
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT02111577: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Official title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Acronym: VIABLE
Sponsor: Sotio Biotech Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1182.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-05-26
Primary completion date: 2020-01-28
Completion date: 2020-01-28
Plan to share individual participant data: NO
Clinical trial NCT02485652: Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Official title: A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Sponsor: Hanmi Pharmaceutical Company Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study termination by the Sponsor
Enrollment: 162.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-08-31
Primary completion date: 2020-12-08
Completion date: 2020-12-08
Clinical trial NCT04480424: Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)
Official title: A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit
Sponsor: Grifols Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-17
Primary completion date: 2021-08-25
Completion date: 2021-10-25
Baseline population: The intent to treat (ITT) population included all participants who were randomized.
Plan to share individual participant data: NO
Clinical trial NCT02695160: Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
Official title: A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
Sponsor: Sangamo Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Enrollment: 1.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-11-15
Primary completion date: 2021-04-19
Completion date: 2021-04-19
Baseline population: All subjects in this study who received any portion of the SB-FIX infusion
Limitations and caveats: Due to the limited sample size of 1 subject, the primary and secondary endpoints could not be analyzed, and this study could not report any conclusions.
Plan to share individual participant data: NO
Clinical trial NCT04607655: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Official title: GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Sponsor: Galecto Biotech AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Due to COVID-19 pandemic and change in the clinical development strategy for the GB1211 compound
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-31
Primary completion date: 2022-07-31
Completion date: 2022-07-31
Plan to share individual participant data: NO
Clinical trial NCT03812224: A Controlled Trial of Erenumab in Migraine Prevention
Official title: A Phase 3 Japanese Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Erenumab in Migraine Prevention
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 261.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-04-12
Primary completion date: 2020-03-16
Completion date: 2020-11-25
Baseline population: The full analysis set (FAS) included all participants who were randomized in the study.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either~1. the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or~2. clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT03880123: Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Official title: A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study will not proceed, no participants enrolled.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-30
Primary completion date: 2020-11-24
Completion date: 2020-11-24
Plan to share individual participant data: NO
Clinical trial NCT02502799: Intervention for Teens With ADHD and Substance Use
Official title: Intervention for Teens With ADHD and Substance Use
Sponsor: Florida International University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Enrollment: 158.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-07-31
Primary completion date: 2021-08-31
Completion date: 2021-08-31
Limitations and caveats: Enrollment in this study fell well short of the planned 300 participants, despite substantial efforts to increase enrollment over the life of the project, and the study was terminated prior to reaching the planned enrollment target. As a result, the number of participants randomized to treatment condition was insufficient to conduct planned analyses. Furthermore, of those participants randomized, many refused assigned treatments.
Clinical trial NCT04252625: Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis
Official title: A Phase II Randomized Controlled Trial of a Supplement Containing Quercetin, Bromelain, Rye Flower Pollen, and Papain on Reducing the Severity of Radiation-Induced Prostatitis
Acronym: Q-Urol
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Drug Supply Issue
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-14
Primary completion date: 2023-12-27
Completion date: 2024-01-25
Plan to share individual participant data: NO
Clinical trial NCT05127525: EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
Official title: Randomized, Double-Masked, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of IRX-101 Versus 5% Povidone-Iodine as an Ocular Surface Sterilizer
Acronym: CLEAN
Sponsor: iRenix Medical, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Adverse event
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-15
Primary completion date: 2022-01-31
Completion date: 2022-01-31
Plan to share individual participant data: NO
Clinical trial NCT05060003: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Official title: A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor made decision to terminate study.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-11-08
Primary completion date: 2023-11-27
Completion date: 2023-11-27
Plan to share individual participant data: NO
Clinical trial NCT05237713: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Official title: A Phase II, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Canakinumab for the Treatment of Anemia in Patients With IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes or MDS/MPN
Sponsor: University of Leipzig (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-26
Primary completion date: 2024-02-29
Completion date: 2024-02-29
Plan to share individual participant data: NO
Clinical trial NCT05550363: A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)
Official title: A Phase 3, Prospective, Randomized, Double-masked, Placebo-controlled, Parallel-design, Multicenter Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
Sponsor: EyePoint Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Not currently pursuing indication
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-30
Primary completion date: 2023-09-30
Completion date: 2023-09-30
Plan to share individual participant data: NO
Clinical trial NCT03436693: Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Official title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Sponsor: Mitsubishi Tanabe Pharma Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 308.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-15
Primary completion date: 2021-01-21
Completion date: 2021-01-21
Clinical trial NCT03745690: Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer
Official title: Phase 1B/2, Open-Label Study Evaluating Safety and Efficacy of Enhanced Permeability and Retention Effect for Near-Infrared Image Guided Surgical Resection of Head and Neck Cancers With Indocyanine Green
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: no enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-12
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Clinical trial NCT05444569: A Study of LY3537021 in Healthy Participants
Official title: A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 47.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-08-08
Primary completion date: 2023-02-24
Completion date: 2023-02-24
Plan to share individual participant data: NO
Clinical trial NCT03301896: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Official title: A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-31
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO